Table 1.

Kappa coefficient between the different PMR-ASs* for the whole population, according to the different cut-off values of the CRP-PMR-AS

	Cut-off 0 to 1.5 vs >1.5 Kappa (95% CI)	Cut-off 0 to 7 vs >7 Kappa (95% CI)	Cut-off 0 to 10 vs >10 Kappa (95% CI)	Cut-off 0 to 17 vs >17 Kappa (95% CI)
CRP-PMR-AS versus ESR-PMR-AS	0.75 (0.70 to 0.80)	0.87 (0.84 to 0.90)	0.90 (0.87 to 0.93)	0.89 (0.86 to 0.93)
CRP-PMR-AS versus clin-PMR-AS	0.91 (0.88 to 0.94)	0.93 (0.90 to 0.95)	0.93 (0.90 to 0.95)	0.94 (0.92 to 0.97)
CRP-PMR-AS versus imp-CRP-PMR-AS	0.92 (.89 to 0.95)	0.92 (0.89 to 0.94)	0.91 (0.89 to 0.94)	0.92 (0.89 to 0.95)

Global kappa coefficient was calculated for the whole population (n=100) of the SEMAPHORE trial at all visits between inclusion and week 24.

The results are presented as kappa coefficients with 95% CIs.

*Details on the activity scores are provided in the caption of figure 1.

AS, activity score; clin, clinical; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; imp, imputed; PMR, polymyalgia rheumatica; SEMAPHORE, Safety and Efficacy of tocilizumab versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence.